<DOC>
	<DOCNO>NCT02786758</DOCNO>
	<brief_summary>This study offer proof concept scale treatment Hepatitis C virus ( HCV ) individual co-infected HIV could lead elimination HCV/HIV co-infection gay bisexual men treat prevalent infection , thereby reduce new primary infection re-infection .</brief_summary>
	<brief_title>Eliminating Hepatitis C Transmission Enhancing Care Treatment Among HIV Co-infected Individuals</brief_title>
	<detailed_description>The co-EC study aim enhance HCV care treatment among HIV-infected individual predominantly nurse-led model care primary care well hospital setting . It involve : 1 . A nurse-led model care primary health care increase access PBS HCV treatment interferon-free HCV antiviral treatment ; 2 . An integrated HCV/HIV surveillance system database deliver monitor impact program local statewide level . The study base Victoria , Australia high prevalence HIV/HCV co-infection gay bisexual men ( GBM ) . HCV infection significant health issue among individual HIV infection associate rapid progression HCV-related liver disease increase risk cirrhosis liver cancer . Hepatitis C major cause hospital admission lead cause death among HIV-infected person . The advent directly act antiviral ( DAA ) treatment provide u unique opportunity increase number people access hepatitis C treatment . Importantly likely treatment could administer primary health care set improve treatment capacity accessibility , whilst potentially reduce treatment cost . The primary objective co-EC Study : 1 . Achieve HCV sustain virological response ( SVR12 ) treatment among HIV co-infected participant real-world primary care hospital clinic setting ; 2 . Measure impact treat HCV HIV infect individual primary HCV reinfection incidence HCV prevalence gay bisexual men Victoria . The study design involve open label , non-randomised clinical trial hepatitis C treatment people HIV coinfection . Treatment involve combination hepatitis C antiviral therapy approve use Australia appropriate participant ' hepatitis C genotype select decision treat clinician .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>1 . Aged ≥18 year ; 2 . Attendance medical care HIV study site ; 3 . Evidence chronic HCV infection ( HCV antibody RNA positive ≥6 month HCV RNA positive ) ; 4 . HIV infect ; 5 . Willing able provide write informed consent ; Subjects must meet routine clinical care criterion commence HCV treatment , accordance Australian licensing , prescribe restriction , manufacturer ' recommendation best practice clinical care . 1 . Pregnancy breastfeed time HCV antiviral treatment ; 2 . Evidence condition , therapy , laboratory abnormality circumstance ( current prior ) may confound study 's result , interfere participation full duration study , best interest participant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>